2011 - Fellow of the American Association for the Advancement of Science (AAAS)
David B. Weiner mostly deals with Virology, Immunology, Immune system, DNA vaccination and Antigen. The Virology study combines topics in areas such as Humoral immunity, Antibody and HIV vaccine. His Immune system research incorporates themes from Cytotoxic T cell and In vivo.
David B. Weiner has included themes like Adjuvant, Electroporation, Cytokine and Immunogenicity in his DNA vaccination study. His Antigen study which covers Biochemistry that intersects with Monoclonal antibody. His research investigates the connection between Virus and topics such as Cell culture that intersect with problems in Myosin.
David B. Weiner focuses on Virology, Immunology, Immune system, DNA vaccination and Antigen. His studies examine the connections between Virology and genetics, as well as such issues in Antibody, with regards to Molecular biology and Recombinant DNA. His research brings together the fields of Cytotoxic T cell and Immunology.
His Immune system study integrates concerns from other disciplines, such as Immunogen and Cytokine. His DNA vaccination research includes themes of HIV vaccine, Immunogenicity, Viral vector, Electroporation and Lentivirus. His studies deal with areas such as Cancer research and Nucleic acid as well as Antigen.
David B. Weiner mainly focuses on Virology, Immune system, DNA vaccination, Immunology and Antigen. His Virology research integrates issues from Plasmid and Antibody, Immunization. His work deals with themes such as Recombinant DNA and Microbiology, which intersect with Antibody.
His study in Immune system is interdisciplinary in nature, drawing from both Cytotoxic T cell and Cancer research. David B. Weiner combines subjects such as Immunogen, Electroporation, Immunity and Immunogenicity with his study of DNA vaccination. His biological study spans a wide range of topics, including Nucleic acid molecule, Nucleic acid and Dysplasia.
His primary scientific interests are in Immunology, Virology, Immune system, DNA vaccination and Antibody. He studied Immunology and Human morbidity that intersect with Subclinical infection, Human cytomegalovirus, Heart disease and Organ transplantation. His study explores the link between Virology and topics such as Recombinant DNA that cross with problems in HIV vaccine.
His research on Immune system often connects related topics like Antigen. David B. Weiner has researched DNA vaccination in several fields, including Immune tolerance, Immunity, Viral Vaccine, Vaccination and Immunogen. His Antibody research includes elements of Immune checkpoint and Microbiology.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors
Erwei Song;Pengcheng Zhu;Sang Kyung Lee;Dipanjan Chowdhury.
Nature Biotechnology (2005)
DNA vaccines: ready for prime time?
Michele A. Kutzler;David B. Weiner.
Nature Reviews Genetics (2008)
Gene inoculation generates immune responses against human immunodeficiency virus type 1.
Bin Wang;Kenneth E. Ugen;Vasantha Srikantan;Michael G. Agadjanyan.
Proceedings of the National Academy of Sciences of the United States of America (1993)
First Human Trial of a DNA-Based Vaccine for Treatment of Human Immunodeficiency Virus Type 1 Infection: Safety and Host Response
Rob Roy MacGregor;Jean D. Boyer;Kenneth E. Ugen;Kim E. Lacy.
The Journal of Infectious Diseases (1998)
p185neu Expression in Human Lung Adenocarcinomas Predicts Shortened Survival
Jeffrey A. Kern;David A. Schwartz;Joanne E. Nordberg;David B. Weiner.
Cancer Research (1990)
Innate Lymphoid Cells Promote Anatomical Containment of Lymphoid-Resident Commensal Bacteria
Gregory F. Sonnenberg;Laurel A. Monticelli;Theresa Alenghat;Thomas C. Fung.
A point mutation in the neu oncogene mimics ligand induction of receptor aggregation
David B. Weiner;Jing Liu;Jeffrey A. Cohen;William V. Williams.
Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial.
Cornelia L Trimble;Matthew P Morrow;Kimberly A Kraynyak;Xuefei Shen.
The Lancet (2015)
Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination.
Jean D. Boyer;Kenneth E. Ugen;Bin Wang;Michael Agadjanyan.
Nature Medicine (1997)
Compositions and methods for delivery of genetic material
David B. Weiner;William V. Williams;Bin Wang;Leslie R. Coney.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: